乌鸦传媒

However, plinabulin plus docetaxel still "not ready for prime time," expert says

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy

Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT

Confirmed responses reached 29.8% in heavily pretreated patients

Randomized data suggest surgery increases risk of death by 28% over first 42 months

Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone

Median overall survival reached 19.3 months in Chinese trial

Long-term follow-up shows continued survival benefit as first-line treatment

Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo

Results show need to integrate sexual health into care, researcher says

Phase II trial supports neoadjuvant nivolumab plus chemotherapy